Business Context and Reporting Period
Company: Akers Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 18, 2017
Event: Entry into a Material Definitive Agreement (Underwriting Agreement) for a public offering of securities.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. The following metrics relate to the securities offering:
- Class A Units Sold: 15,500,000 units at $0.15 per unit.
- Class B Units Sold: 3,675 units at $1,000 per unit.
- Common Stock Issued: 15,500,000 shares (via Class A) plus 3,675 shares of Series B Convertible Preferred Stock (convertible into 24,500,000 shares of Common Stock).
- Warrants Issued: Warrants to purchase 15,500,000 shares (Class A) and 24,500,000 shares (Class B).
- Warrant Terms: Exercise price of $0.1875 per share; exercisable immediately; expiration date of December 21, 2022.
- Over-allotment Option: Underwriter granted a 45-day option to purchase up to an additional 6,000,000 shares of Common Stock and corresponding warrants.
Operational Metrics: The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes Versus Prior Period
The filing does not provide comparative financial data or operational metrics to assess changes versus a prior period. The primary material change is the execution of the underwriting agreement and the subsequent increase in authorized and outstanding equity securities.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on December 18, 2017, announcing the pricing of the Offering (incorporated as Exhibit 99.1). The filing does not contain specific forward-looking guidance or management commentary beyond the transaction details.
Risks and Contingencies: The filing notes that the description of the Underwriting Agreement is qualified in its entirety by reference to the full text of the agreement (Exhibit 1.1). No specific risk factors or contingencies are detailed within the body of this 8-K summary.
Important Facts for Investor Verification
- Verify the total gross proceeds from the offering by calculating the sum of Class A and Class B unit sales.
- Review the full Underwriting Agreement (Exhibit 1.1) for details on underwriting discounts, commissions, and specific covenants.
- Confirm the dilution impact of the 39,000,000 total warrants issued and the potential conversion of 24,500,000 shares from Series B Preferred Stock.
- Monitor the exercise of the 45-day over-allotment option for an additional 6,000,000 shares.
- Check the press release (Exhibit 99.1) for the stated use of proceeds from this capital raise.